First National Advisers LLC Increases Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

First National Advisers LLC lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,914 shares of the medical equipment provider’s stock after acquiring an additional 1,098 shares during the period. First National Advisers LLC’s holdings in Lantheus were worth $2,497,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new position in Lantheus in the third quarter valued at approximately $25,000. Kestra Investment Management LLC purchased a new position in Lantheus in the fourth quarter valued at approximately $27,000. UMB Bank n.a. raised its holdings in Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares during the period. World Investment Advisors LLC acquired a new stake in Lantheus in the third quarter valued at approximately $60,000. Finally, RiverPark Advisors LLC acquired a new stake in Lantheus in the third quarter valued at approximately $74,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on LNTH shares. Truist Financial raised their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Finally, The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $132.86.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Up 1.8 %

Shares of LNTH opened at $101.10 on Friday. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89. The firm has a market capitalization of $6.92 billion, a PE ratio of 16.82 and a beta of 0.38. The stock’s fifty day simple moving average is $92.07 and its 200-day simple moving average is $96.77.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.